OneMedNet Regains Compliance with NASDAQ Listing Requirements

Rhea-AI Summary

OneMedNet (ONMD) has regained compliance with Nasdaq Listing Rule 5550(b)(2) after its common stock market value exceeded $35,000,000 for 10 consecutive business days. The company has cleared all listing deficiency notices issued by Nasdaq.

Throughout 2024-2025, OneMedNet implemented several strategic initiatives, including: expanding product offerings with data masking solutions and subscription-based services; appointing key executives including Bob Golden as CFO; signing an agreement with Bayer's AI Innovation Platform; enhancing data de-identification services with Generative AI; deploying the OMNi 2.0 indexer; refreshing the Board of Directors; and improving liquidity through $6.4M in private placements with Off the Chain Capital and Discovery Capital Management affiliate. The company also implemented a Bitcoin treasury management strategy.

Positive

• Regained Nasdaq compliance, eliminating delisting risk
• Secured $6.4M through private placements
• Expanded product offerings with new data masking solutions
• Signed agreement with Bayer's AI Innovation Platform
• Enhanced data services with Generative AI implementation

Negative

• None.

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the “Rule”) after the market value of the Company’s common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.   As a result, the Company has cleared all listing deficiency notices issued by Nasdaq.

Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue and business operations.”

During the 2024 and 2025, we developed and started to execute on our strategic plan by:

• Expanding its product offerings, which now include data masking solutions for additional industries and subscription-based offerings for the Company’s healthcare and real-world data solutions.
• Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company’s financial reporting processes.
• Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December 2024.
• Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
• Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
• Improving liquidity by raising approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.
• Enhancing treasury management with a Bitcoin on the balance sheet strategy.

OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.

About OneMedNet Corporation

OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.

OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

FAQ

How did OneMedNet (ONMD) regain Nasdaq compliance in 2025?

OneMedNet regained compliance with Nasdaq Listing Rule 5550(b)(2) after its market value exceeded $35,000,000 for 10 consecutive business days.

How much funding did ONMD raise in private placements?

OneMedNet raised approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.

What strategic partnerships did ONMD secure in 2024?

OneMedNet signed an agreement with Bayer's AI Innovation Platform (AIIP) in early December 2024.

What technological improvements did ONMD implement in 2024-2025?

OneMedNet enhanced its Data De-Identification service with Generative AI and deployed the 2.0 generation indexer OMNi for improved data searching and indexing.

What new financial strategy did ONMD implement for treasury management?

OneMedNet implemented a Bitcoin on the balance sheet strategy for treasury management.